Evidence map›Paper›PMID 35216113›Full record

ArticleInternational journal of molecular sciences2022

The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.

Eligija Damanskienė, Ingrida Balnytė, Angelija Valančiūtė, Marta Maria Alonso, Aidanas Preikšaitis, Donatas Stakišaitis

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Eligija DamanskienėDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Ingrida BalnytėDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Angelija ValančiūtėDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.ORCID 0000-0003-3611-2509
Marta Maria AlonsoDepartment of Pediatrics, Clínica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-7520-7351
Aidanas PreikšaitisCentre of Neurosurgery, Clinic of Neurology and Neurosurgery, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.
Donatas StakišaitisDepartment of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.ORCID 0000-0002-1547-7050
Lithuanian University of Health Sciences · LTClinica Universidad de Navarra · ESVilnius University · LT

Funding

Lietuvos Mokslo Taryba grant number P-MIP-20-36
6 · The paper itself

Abstract

It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms. The study aimed to investigate the TMZ 50 and 100 μM dose effect difference between PBT24 and SF8628 cell line high-grade pediatric glioblastoma (phGBM) xenografts in a chicken chorioallantoic membrane (CAM) model, on PCNA and EZH2 immunohistochemical expression in the tumor and on the expression of NKCC1, KCC2, E- and N-cadherin genes in TMZ-treated and control cell groups in vitro. TMZ at a 100 μg dose reduced the incidence of PBT24 xenograft invasion into the CAM, CAM thickening and the number of blood vessels in the CAM (

Indexed as

AnimalsAntineoplastic Agents, AlkylatingApoptosisBrain NeoplasmsCarcinogenesisCell Line, TumorCell ProliferationChickensChorioallantoic MembraneDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGlioblastomaHumansMaleRatsTemozolomideAntineoplastic Agents, AlkylatingTemozolomideCAMEZH2KCC2NKCC1PCNApediatric glioblastomatemozolomide

Identifiers

PMID35216113
PMCPMC8877228
OpenAlexW4212963397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.